Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Rockwell Medical (RMTI) over the last 16 years, with Dec 2024 value amounting to $475,000.

  • Rockwell Medical's Current Deferred Revenue fell 8.83% to $475,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $475,000, marking a year-over-year decrease of 8.83%. This contributed to the annual value of $475,000 for FY2024, which is 8.83% down from last year.
  • Rockwell Medical's Current Deferred Revenue amounted to $475,000 in Q4 2024, which was down 2.46% from $487,000 recorded in Q3 2024.
  • Rockwell Medical's 5-year Current Deferred Revenue high stood at $11.6 million for Q1 2020, and its period low was $475,000 during Q4 2024.
  • In the last 3 years, Rockwell Medical's Current Deferred Revenue had a median value of $1.6 million in 2023 and averaged $2.9 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 417.33% in 2020, then slumped by 92.08% in 2023.
  • Quarterly analysis of 5 years shows Rockwell Medical's Current Deferred Revenue stood at $10.2 million in 2020, then declined by 19.95% to $8.2 million in 2021, then slumped by 46.90% to $4.3 million in 2022, then slumped by 87.97% to $521,000 in 2023, then declined by 8.83% to $475,000 in 2024.
  • Its Current Deferred Revenue stands at $475,000 for Q4 2024, versus $487,000 for Q3 2024 and $498,000 for Q2 2024.